NEW YORK — Genosity said on Tuesday that it has entered into a nonexclusive comarketing alliance with cancer genomics firm Personal Genome Diagnostics (PGDx).
Under the terms of the deal, Genosity will incorporate PGDx's Elio Tissue Complete — a US Food and Drug Administration-cleared next-generation sequencing assay used for the genomic profiling of cancer — into its software platform and professional consulting services. Genosity said it will preconfigure its laboratory information management system workflows for the assay, as well as integrate its Case Analyzer application for variant interpretation, case analysis, and clinical result report writing into PGDx’s bioinformatic pipeline so that labs can integrate assay results into physician centric reports.
Baltimore-based PGDx, meanwhile, will comarket Genosity's Integrated Genomic Toolkit, a HIPAA-compliant end-to-end software platform for clinical NGS laboratory workflows.
Additional terms were not disclosed.
In early 2019, Iselin, New Jersey-based Genosity signed an agreement to comarket its line of consulting and laboratory software services with ArcherDx.